Physician profile
Rachael F Grace
NPI 1144335100
$200,874.35
in general payments reported to CMS, 2019-2025
8 companies · $35K in 2025
The $35K reported for 2025 was more than what 95% of Pediatric Hematology-Oncology providers received nationally (typical 2025 total: $207).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $40K · 2020: $62K · 2021: $8,880 · 2022: $11K · 2023: $7,643 · 2024: $37K · 2025: $35K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $47K · Consulting Fee: $26K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,364 · Honoraria: $2,220 · Food and Beverage: $286.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $46,728.39 |
| Consulting Fee | $26,372.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,364.00 |
| Honoraria | $2,220.00 |
| Food and Beverage | $285.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Agios Pharmaceuticals, INC. | $161,210.09 | 2019-2025 | Pyrukynd |
| Swedish Orphan Biovitrum Ab | $22,555.33 | 2024 | |
| Novartis Pharmaceuticals Corporation | $5,440.00 | 2020 | |
| Genzyme Corporation | $3,740.00 | 2024 | |
| Sanofi US Services INC. | $3,364.00 | 2025 | |
| Dova Pharmaceuticals | $3,109.75 | 2019-2020 | |
| Sobi, INC | $1,455.18 | 2024 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachael Grace listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.